Last reviewed · How we verify
Matching placebo to sitagliptin
Matching placebo to sitagliptin is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus.
This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.
This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient. Used for Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus.
At a glance
| Generic name | Matching placebo to sitagliptin |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
In clinical trials, a matching placebo is designed to be indistinguishable from the active drug (sitagliptin in this case) to maintain blinding. The placebo arm serves as a control to assess the true efficacy and safety of sitagliptin by comparison. Sitagliptin itself is a DPP-4 inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose.
Approved indications
- Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers (PHASE1)
- Cardiovascular Effects of GLP-1 Receptor Activation (PHASE4)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients (PHASE3)
- Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo to sitagliptin CI brief — competitive landscape report
- Matching placebo to sitagliptin updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Matching placebo to sitagliptin
What is Matching placebo to sitagliptin?
How does Matching placebo to sitagliptin work?
What is Matching placebo to sitagliptin used for?
Who makes Matching placebo to sitagliptin?
What development phase is Matching placebo to sitagliptin in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Control arm in phase 3 trial of sitagliptin for type 2 diabetes mellitus
- Compare: Matching placebo to sitagliptin vs similar drugs
- Pricing: Matching placebo to sitagliptin cost, discount & access